I went to Ernst & Young‘s Toronto presentation of this year’s Beyond Borders global biotech report (PDF) recently. The report is a retrospective of 2009, so many of the data points and trends reflect things you’ve seen already; but as always, I’d encourage you to read the whole thing for good synthesis and commentary.
E&Y’s headline was: 2009 showed strong overall sector performance including global profitability, which was largely buoyed by U.S. profits (good) and by a global reduction in R&D spending (bad).
The Canadian data generally reflected global trends:
- Canadian biotech revenues were up 9% over last year; but
- R&D spending in Canada was down 44%; and
- The number of Canadian public companies was down from 72 to 60
To read the full, original article click on this link: E&Y Beyond Borders Biotech Report 2010 — Canadian Biotech Data « The RIC Blog
Author: Jeremy Grushcow
